Herpes zoster prophylaxis: Essential for treating newly diagnosed multiple myeloma patients
Wen-Ying Lin1, Chun-Kuang Tsai2,3, Chiu-Mei Yeh2,4
1Department of Medicine, Taipei Veterans General Hospital, Taipei, Taiwan.
Background:
Multiple myeloma (MM) is known for its immune disturbance and patients suffering from MM are thus vulnerable to opportunistic infections, including herpes zoster (HZ). As HZ infection remarkably affects patients' quality of life and poses huge economic burdens on the health system, we aim to identify the risk factors of HZ infection and evaluate the effects of different dosages, types, and durations of anti-HZ prophylaxis drugs to prevent HZ infection.
Methods:
551 MM patients at Taipei Veterans General Hospital in Taiwan between January 1, 2009 and August 31, 2021 were restrospectively analyzed. The patients' baseline characteristics were recorded. The primary endpoint of the study was the incidence of HZ infection among the studied patient population. Due to the lack of cost coverage from Taiwanese public health insurance on HZ prophylaxis drugs, the use of anti-HZ drugs mainly depends on physicians' preferences and patients' choices.
Results:
In our study, prophylaxis was given to 283 of the patients. In the multivariate analysis, we included non-prophylaxis, age ≥ 60, corrected serum calcium ≥12 mg/dl, serum creatinine ≥2 mg/dl, serum β2-microglobulin ≥5500 mg/L, autologous stem cell transplant (SCT), and allogeneic SCT for analysis. Our results demonstrated that the non-prophylaxis group (HR: 2.37, 95% CI 1.57-3.57) and patients receiving autologous SCT (HR: 2.22, 95% CI 1.28-3.86) and allogeneic SCT (HR: 5.12, 95% CI 1.13-23.22) had higher risk of HZ infection. The difference in dosage and types of anti-HZ drugs showed similar protective effects. In patients who stopped anti-HZ prophylaxis before active cancer-related treatment, a higher risk of getting HZ infection compared to the corresponding group was also observed (adjusted HR 3.09, 95% CI 1.35-7.07, p = 0.008).
Conclusions:
We concluded that MM patients should receive HZ prophylaxis drugs while receiving active cancer-related treatment. Patients receiving SCT are also at high risk of getting HZ infection, even under prophylaxis.
Insights
Multiple myeloma patients are vulnerable to herpes zoster (HZ) infections. Continuing HZ prophylaxis during cancer treatment is crucial, especially for those undergoing stem cell transplant (SCT).
Area of Science:
- Oncology
- Infectious Diseases
- Pharmacology
Background:
- Multiple myeloma (MM) compromises immune function, increasing susceptibility to opportunistic infections like herpes zoster (HZ).
- HZ infection significantly impacts patient quality of life and healthcare costs.
- Identifying HZ risk factors and optimizing prophylaxis strategies in MM patients is essential.
Purpose of the Study:
- To identify risk factors for HZ infection in multiple myeloma patients.
- To evaluate the effectiveness of anti-HZ prophylaxis drugs regarding dosage, type, and duration.
- To inform clinical practice for HZ prevention in MM patients.
Main Methods:
- Retrospective analysis of 551 MM patients at Taipei Veterans General Hospital (2009-2021).
- Data collection included patient characteristics and HZ infection incidence.
- Multivariate analysis assessed risk factors including age, renal function, SCT, and prophylaxis status.
Main Results:
- Non-prophylaxis, autologous SCT, and allogeneic SCT were associated with significantly higher HZ infection risk.
- Different dosages and types of anti-HZ drugs demonstrated comparable protective effects.
- Discontinuing prophylaxis before active cancer treatment increased HZ risk (aHR 3.09).
Conclusions:
- MM patients require HZ prophylaxis throughout active cancer-related treatment.
- Stem cell transplant (SCT) recipients remain at high risk for HZ infection, even with prophylaxis.
- Continued vigilance and adherence to prophylaxis are recommended for high-risk MM patients.
Related Concept Videos
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
Phenothiazines, such as prochlorperazine...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Myocarditis IV: Nursing Management
Treatment Resistant Cancers


